A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaShifu Xiao, Raoli He, Weihong Kuang et al.|Alzheimer s Research & Therapy|2021Cited by 200
Personalized risk prediction of symptomatic intracerebral hemorrhage after stroke thrombolysis using a machine-learning modelFeng Wang, Yuwu Zhao, Bruce Campbell et al.|Therapeutic Advances in Neurological Disorders|2020Cited by 44